Nano-enzyme drug delivery system for targeted therapy of inflammatory bowel disease as well as preparation method and application of nano-enzyme drug delivery system
By using carrier mesoporous Se nanozyme and enteric-coated MyD88 inhibitor INNA1605 in the treatment of inflammatory bowel disease, the problems of poor drug targeting and major side effects were solved, and more efficient intestinal targeting treatment was achieved. Reduces systemic exposure and side effects.
Patent Information
- Application Number
- CN202411246521.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-12-03
AI Technical Summary
In the treatment of inflammatory bowel disease, the drug is poorly targeted, the systemic exposure is large, and the side effects are obvious, making it difficult to simultaneously remove reactive oxygen species and inhibit proinflammatory cytokines.
A nanoenzyme drug delivery system is developed, including the carrier mesoporous Se nanoenzyme and the drug MyD88 inhibitor INNA1605, and is coated with enteric coating to improve drug targeting and intestinal localization.
It significantly improves the unit effective dose and targeting of MyD88 inhibitor, enhances the therapeutic effect on inflammatory bowel disease, reduces systemic exposure and side effects, and improves the accumulation and bioavailability of drugs in the colon.
Smart Images

Figure CN119055794A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical materials, and in particular to a nanozyme drug delivery system for targeted treatment of inflammatory bowel disease, and a preparation method and application thereof. Background Art
[0002] Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a complex, chronic, nonspecific intestinal inflammatory disease. Its global incidence continues to rise, placing a heavy economic and social burden on the public health system. The pathogenesis of IBD is complex, involving the interaction of multiple factors such as genetics, environment, immunity, and microorganisms. Among them, oxidative stress and inflammatory response are the core links in the pathological process of IBD, manifested as excessive production of reactive oxygen species (ROS) and the release of multiple proinflammatory cytokines. These processes together aggravate the damage of the intestinal barrier and the imbalance of the intestinal microbiota.
[0003] Excessive production of ROS not only directly causes tissue damage, but also further upregulates the expression of proinflammatory cytokines such as TNF-α, IL-1β and IL-6 by activating signaling pathways such as NF-κB, forming a vicious cycle and exacerbating the inflammatory response. As a key adaptor protein in the TLR / IL-1R signaling pathway, MyD88 overactivation plays an important role in the inflammatory response of IBD. Therefore, inhibiting the MyD88 signaling pathway has become one of the potential strategies for the treatment of IBD.
[0004] In recent years, nanotechnology has made significant progress in the field of drug delivery, especially the application of nanozymes has provided new ideas for the treatment of IBD. Nanozymes, such as selenium (Se)-based nanozymes, not only have excellent biocompatibility and antioxidant capacity, but also can achieve targeted delivery and controlled release of drugs through their unique nanostructures, thereby improving the therapeutic effect and reducing side effects. In particular, selenium-based nanozymes such as WSe2 have been found to effectively scavenge ROS, regulate intestinal microbiota and inhibit T cell differentiation, thus showing great potential in the treatment of IBD.
[0005] However, although MyD88 inhibitors or nanozymes alone can achieve certain therapeutic effects, there are still problems such as poor drug targeting, large systemic exposure, and obvious side effects. Therefore, it is particularly important to develop a new drug delivery system that can simultaneously remove ROS, inhibit proinflammatory cytokines, and have good targeting.
[0006] In view of this, the present invention creatively provides a nanozyme drug delivery system loaded with an aminothiazole compound MyD88 inhibitor, including a carrier mesoporous Se nanozyme and a loaded drug MyD88 inhibitor INNA1605, which can simultaneously clear ROS and inhibit proinflammatory cytokines, and promote the MyD88 inhibitor to target intestinal lesions, thereby achieving better therapeutic effects, lower systemic exposure, and reduced side effects. Summary of the invention
[0007] In order to solve the above problems, the object of the present invention is to provide a nanozyme drug delivery system for targeted treatment of inflammatory bowel disease and its preparation method and application. The nanozyme drug delivery system includes a carrier mesoporous Se nanozyme and a loaded drug MyD88 inhibitor INNA1605, and is wrapped with an enteric coating to reduce dissolution and release in the stomach. The present invention provides a new method for improving the systemic tissue and organ distribution of INNA1605 drugs and enhancing the effect of INNA1605 in treating IBD.
[0008] The present invention provides a nanozyme drug delivery system for targeted treatment of inflammatory bowel disease. The nanozyme drug delivery system comprises a mesoporous nanozyme and a MyD88 inhibitor loaded in the mesoporous channels of the mesoporous nanozyme.
[0009] As a further optimization scheme of the present invention, the MyD88 inhibitor is an aminothiazole compound INNA1605, and its chemical structure is as follows:
[0010]
[0011] As a further optimization scheme of the present invention, the average particle size of the mesoporous nanozyme is 180 to 210 nm, and the pore diameter of the mesopore is 4 to 10 nm.
[0012] As a further optimization scheme of the present invention, the mesoporous nanozyme includes at least one of mesoporous selenium nanozyme, tungsten diselenide, cerium oxide, silicon dioxide, and CuFe2O4.
[0013] As a further optimization scheme of the present invention, the nanozyme drug delivery system also includes a coating, and the coating is an enteric coating or a gastric coating.
[0014] The present invention provides a method for preparing a nanozyme drug delivery system for targeted treatment of inflammatory bowel disease, comprising the following steps:
[0015] Preparation of mesoporous nanozymes;
[0016] The MyD88 inhibitor is loaded onto the mesoporous nanozyme to form a MyD88 inhibitor-loaded complex;
[0017] The complex is combined with at least one auxiliary component and prepared into a nanoenzyme drug delivery system through spray drying technology.
[0018] As a further optimization scheme of the present invention, the steps of preparing the mesoporous selenium nanozyme include:
[0019] Synthesis of aminated mesoporous silica as a hard template;
[0020] Dispersing aminated mesoporous silica in a solvent, adding a selenium source and stirring;
[0021] In the presence of a reducing agent, a selenium source is reacted with aminated mesoporous silica to form a mesoporous selenium nanozyme;
[0022] The excess aminated mesoporous silica was removed by chemical treatment to obtain pure mesoporous selenium nanozyme.
[0023] As a further optimization scheme of the present invention, the steps of synthesizing aminated mesoporous silica include:
[0024] At room temperature, the surfactant is dissolved in a mixed solution of ethanol and deionized water, and stirred to form a uniform solution;
[0025] The pH value of the solution is adjusted to alkaline, and a silicon source is added to perform hydrolysis and polycondensation reactions to form a mesoporous silica structure;
[0026] The aminosilane coupling agent is reacted with the obtained mesoporous silica to obtain aminated mesoporous silica.
[0027] The present invention also provides an application of the nanozyme drug delivery system for targeted treatment of inflammatory bowel disease in the preparation of drugs for treating inflammatory bowel disease.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The present invention relates to the use of a nanozyme drug delivery system loaded with a MyD88 inhibitor (aminothiazole compound) for the treatment of IBD. The delivery system can better treat IBD than a single oral MyD88 inhibitor or nanozyme. Nanozyme mesopores increase the unit effective dose and targeting of the MyD88 inhibitor INNA1605, and assist in anti-inflammatory treatment. Enteric coating promotes a significant increase in the intestinal bioavailability of INNA1605, thereby improving the therapeutic effect of INNA1605 on IBD. Through these effects, the nanozyme delivery system of aminothiazole compound MyD88 inhibitor is expected to provide a new strategy and method for alleviating and treating IBD. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1The distribution of INNA1605 in plasma, stomach, small intestine and colon at different time points after a single oral administration of INNA1605 or INNA / MSe / Eu nanozyme.
[0031] Figure 2 After a single oral administration of INNA1605 or INNA / MSe / Eu nanozyme, the AUC (area under the drug-time curve) of INNA1605 in each tissue was calculated, and statistical analysis was performed to reflect the changes in the content of INNA1605 in different tissues.
[0032] Figure 3 The weight changes of mice in different groups during the whole experiment of treating colitis mice with INNA1605 or INNA / MSe / Eu nanozymes by oral administration.
[0033] Figure 4 The changes in DAI scores of mice in different groups during the overall experimental process of treating colitis mice with INNA1605 or INNA / MSe / Eu nanozymes administered orally.
[0034] Figure 5 This is the survival curve of mice in different groups during the overall experimental process of treating colitis mice with INNA1605 or INNA / MSe / Eu nanozymes administered orally.
[0035] Figure 6 On the 10th day after intragastric administration of INNA1605 or INNA / MSe / Eu nanozyme to treat colitis mice, the colon lengths of mice in different groups were measured and statistically analyzed. DETAILED DESCRIPTION
[0036] The present invention is further described in detail below in conjunction with the accompanying drawings, embodiments and experimental examples. Of course, the protection scope of the present invention is not limited to the following embodiments. Professional and technical personnel in the field can understand that various changes and modifications can be made to the present invention without departing from the spirit of the present invention. The present invention generally and / or specifically describes the materials and test methods used in the experiment. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described as detailed as possible here. The following examples further illustrate the present invention, rather than limiting the present invention. Any equivalent transformation that is only formal and not substantial based on the concept of the present invention should be regarded as the scope of the technical solution of the present invention.
[0037] The experimental methods or test methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials are obtained from conventional commercial channels or prepared by conventional methods unless otherwise specified.
[0038] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0039] Example 1: Preparation method of a nanozyme drug delivery system loaded with aminothiazole compound MyD88 inhibitor
[0040] Synthesis of aminated mesoporous silica (MSN) as a "hard template":
[0041] At room temperature, 0.265 g of hexadecyltrimethylammonium bromide (CTAB) was dissolved in a mixed solution of 7.5 ml of ethanol and 65 ml of deionized water. The solution was stirred at 26 °C for 30 min using a magnetic stirrer. An appropriate amount of NH3·H2O was slowly added to the solution and the pH value was adjusted to 9-10. After continuing to stir for 5 minutes, 200 μL of tetraethylorthosilicate (TEOS) was added. The solution temperature was raised to 60 °C and stirred continuously. Stirring was continued at 60 °C for 12 hours to complete the hydrolysis and polycondensation reaction of the silicon source to form a mesoporous silica structure. Aminopropyltriethoxysilane (APTES) was added to react with the product for 12 hours to obtain MSN.
[0042] Preparation of mesoporous selenium nanozyme (MSe):
[0043] 2 mg / mL MSN (5 mL) was prepared, and then 5 mg / mL sodium selenite (5 mL) was added to the solution and stirred well for 30 minutes, and then ascorbic acid was slowly added to react for 3 hours. Finally, 200 L of HF was added to the solution and lyophilized by centrifugation to obtain MSe.
[0044] Preparation of INNA / MSe / Eu nanozyme delivery system:
[0045] INNA1605 solution was added and stirred at room temperature. After 12 hours, the supernatant was removed by centrifugation at 15000 g for 5 minutes and washed twice with deionized water to obtain INNA / MSe, which was mixed with enteric coating shell Eudragit L100 and finally prepared microspheres by spray drying technology to obtain INNA / MSe / Eu nanozyme delivery system.
[0046] Example 2: Effect of INNA / MSe / Eu nanozyme delivery system on the distribution of INNA1605 in different tissues and organs.
[0047] A colitis model was established in 6-8 week old BALB / c male mice by giving them free access to 5% dextran sulfate sodium (DSS) aqueous solution for 5 days. On the 6th day, mice with colitis were given a single intragastric administration of 50 mg / kg of INNA1605 or INNA / MSe / Eu nanozyme delivery system (50 mg / kg INNA1605), and were euthanized at different time points (0.5, 2, 4, 6, 12 and 24 h) after intragastric administration. The plasma, stomach, small intestine and colon of mice were obtained, and the concentration of INNA1605 was determined by LC / MS method to understand the concentration and distribution of INNA1605 in vivo under different delivery systems.
[0048] Please refer to Figure 1 and Figure 2 , the experimental results showed that the concentration of INNA1605 in the stomach decreased rapidly. For the drug concentration in plasma, the INNA1605 group reached the highest after 2 hours, while the INNA / MSe / Eu group reached the peak after 6 hours. In addition, the small intestinal drug concentration of the INNA / MSe / Eu group was higher than that of the INNA1605 group, but the opposite was true in plasma. This difference was mainly due to the fact that the enteric coating delayed the release of the drug and reduced its absorption in the stomach. Further, the drug accumulation in the colon of different delivery systems reached the highest value at 6 hours. In particular, the INNA / MSe / Eu delivery system significantly increased the concentration of INNA1605 in the colon. From the area under the concentration-time curve of each tissue, the INNA / MSe / Eu delivery system made the drug more concentrated in the colon, while the distribution in plasma was relatively low compared with the nanozyme-free delivery system. This feature is very beneficial for the targeted treatment of colitis because it can increase the therapeutic effect while reducing the systemic drug exposure, thereby reducing possible side effects.
[0049] Example 3: Therapeutic effect of INNA / MSe / Eu nanozyme delivery system on IBD.
[0050] A colitis model was established using 6-8 week old BALB / c male mice by giving them free access to a 5% dextran sulfate sodium (DSS) aqueous solution for 5 days. On day 6, the colitis mice were divided into three groups and treated with PBS, INNA1605, and INNA / MSe / Eu, respectively, by gavage once a day for 10 consecutive days. The dosage of INNA1605 in different groups was consistent at 50 mg / kg. During this period, the body weight, stool morphology, and fecal blood of the mice were monitored to assess the disease status. At the end of the experiment, the mice were euthanized and the colons were collected for colon length analysis and pathological analysis.
[0051] Please refer to Figure 3-Figure 6 The model mice experienced a sharp weight loss during the modeling period, accompanied by a significant increase in the disease activity index (DAI) score. Mice treated with PBS did not show any signs of improvement. In contrast, the INNA / MSe / Eu group showed a better treatment effect than the INNA1605 group, as reflected in the recovery of body weight and the reduction of DAI scores. In addition, the difference in treatment effect can also be seen by observing the survival rate of mice in each group. The PBS group had a high mortality rate, with a survival rate of only 14.2%, while the survival rate of the INNA1605 group was 75%, and the INNA / MSe / Eu group reached 100.0%. This result is consistent with the trend observed in weight change and DAI score. As an important indicator for assessing the severity of acute colitis, colon length was also measured. The results showed that the colon length of the model group was significantly shortened compared with the control group. However, the INNA / MSe / Eu group showed a more significant effect in restoring colon length compared with the INNA1605 group.
[0052] Therefore, the INNA / MSe / Eu nanozyme drug delivery system preparation provided by the present invention has a colon-localized drug release effect, and can quickly release drugs, effectively treat IBD, increase the therapeutic effect while reducing systemic drug exposure, thereby reducing possible side effects.
[0053] In summary, the drug for treating inflammatory bowel disease provided by the present invention can achieve effective treatment of colitis through oral administration, has stronger immunomodulatory effect than INNA1605 or nanozyme alone, and has a synergistic therapeutic effect. At the same time, the delivery system improves the accumulation and targeting of INNA1605 in the colon, reduces the concentration in plasma, and reduces the liver metabolic burden and cardiac toxicity that may be caused by systemic exposure of the drug, thereby achieving better therapeutic effects.
[0054] The above are only preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be regarded as limiting the present invention, and the protection scope of the present invention should be based on the scope defined by the claims. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. A nanozyme drug delivery system for targeted treatment of inflammatory bowel disease, characterized in that: The nanozyme drug delivery system comprises a mesoporous nanozyme and a MyD88 inhibitor loaded in the mesoporous channels of the mesoporous nanozyme.
2. The nanozyme drug delivery system for targeted treatment of inflammatory bowel disease according to claim 1, characterized in that: The MyD88 inhibitor is an aminothiazole compound INNA1605, and its chemical structure is as follows:
3. The nanozyme drug delivery system for targeted treatment of inflammatory bowel disease according to claim 1, characterized in that: The average particle size of the mesoporous nanozyme is 180-210 nm, and the pore diameter of the mesopore is 4-10 nm.
4. The nanozyme drug delivery system for targeted treatment of inflammatory bowel disease according to claim 1, characterized in that: The mesoporous nanozyme includes at least one of mesoporous selenium nanozyme, tungsten diselenide, cerium oxide, silicon dioxide, and CuFe2O4.
5. The nanozyme drug delivery system for targeted treatment of inflammatory bowel disease according to claim 1, characterized in that: The nanozyme drug delivery system also includes a coating.
6. The nanozyme drug delivery system for targeted treatment of inflammatory bowel disease according to claim 5, characterized in that: The coating is an enteric coating or a gastric coating.
7. A method for preparing a nanozyme drug delivery system for targeted treatment of inflammatory bowel disease as claimed in any one of claims 1 to 6, characterized in that: The steps include: Preparation of mesoporous nanozymes; The MyD88 inhibitor is loaded onto the mesoporous nanozyme to form a MyD88 inhibitor-loaded complex; The complex is combined with at least one auxiliary component and prepared into a nanoenzyme drug delivery system through spray drying technology.
8. The method for preparing the nanozyme drug delivery system for targeted treatment of inflammatory bowel disease according to claim 7, characterized in that: The steps of preparing mesoporous selenium nanozyme include: Synthesis of aminated mesoporous silica as a hard template; Dispersing aminated mesoporous silica in a solvent, adding a selenium source and stirring; In the presence of a reducing agent, a selenium source is reacted with aminated mesoporous silica to form a mesoporous selenium nanozyme; The excess aminated mesoporous silica was removed by chemical treatment to obtain pure mesoporous selenium nanozyme.
9. The method for preparing the nanozyme drug delivery system for targeted treatment of inflammatory bowel disease according to claim 8, characterized in that: The steps for synthesizing aminated mesoporous silica include: At room temperature, the surfactant is dissolved in a mixed solution of ethanol and deionized water, and stirred to form a uniform solution; The pH value of the solution is adjusted to alkaline, and a silicon source is added to perform hydrolysis and polycondensation reactions to form a mesoporous silica structure; The aminosilane coupling agent is reacted with the obtained mesoporous silica to obtain aminated mesoporous silica.
10. Use of the nanozyme drug delivery system for targeted treatment of inflammatory bowel disease as claimed in any one of claims 1 to 6 in the preparation of drugs for treating inflammatory bowel disease.
Citation Information
Cited By
Mucosal epithelial cell targeted oral ROS responsive nano-enzyme as well as preparation method and application of mucosal epithelial cell targeted oral ROS responsive nano-enzyme
CN121313671A
